scispace - formally typeset
E

Ebrahim Barkoudah

Researcher at Brigham and Women's Hospital

Publications -  44
Citations -  548

Ebrahim Barkoudah is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 28 publications receiving 400 citations. Previous affiliations of Ebrahim Barkoudah include Harvard University & University of Tennessee Health Science Center.

Papers
More filters
Journal ArticleDOI

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

TL;DR: Recurrent MI or cardiac rupture accounts for a high proportion of sudden death in the early period after acute MI, whereas arrhythmic death may be more likely subsequently, helping explain the lack of benefit of early implantable cardioverter-defibrillator therapy.
Journal ArticleDOI

Mortality Rates in Trials of Subjects With Type 2 Diabetes

TL;DR: Although the mortality rates were higher in RCTs with prior cardiovascular morbidity, the selection for chronic kidney disease—defined by either higher serum creatinine or lower estimated glomerular filtration rate and/or the presence of proteinuria—was associated with the highest mortality rates.
Journal ArticleDOI

The permissive role of endothelial NO in CO-induced cerebrovascular dilation.

TL;DR: It is suggested that endothelium-derived NO stimulates guanylyl cyclase in vascular smooth muscle cells and, thereby, permits CO to cause dilation by activating K(Ca) channels.
Journal ArticleDOI

Renal responses to three types of renin–angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

TL;DR: The relative resistance of the renal renin response to acute and chronic renin–angiotensin system blockade supports the concept of an activated renal renIn–angiotsin system in diabetes, particularly at the level of the juxtaglomerular cell, and implies that diabetic patients might require higher doses of renin-angiotENSin system blockers to fully suppress the kidneys.
Journal ArticleDOI

COVID-19 and Rhabdomyolysis.

TL;DR: Internal Medicine Residency Program, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, BrighamandWomen”s hospital and HarvardMedical School,Boston,MA, USA.